Ritmax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ritmax

Ritmax is a synthetic, single-ingredient pharmaceutical used to stabilize the heart's rhythm. Its core composition is the active substance Amiodarone Hydrochloride, which is defined by its ability to modulate the heart's electrical signals. This medication is available in two main formats: an oral tablet for sustained therapy and an injection solution intended for immediate, intravenous administration in critical situations.

Property Description
Active ingredient Amiodarone Hydrochloride
Form Tablet, Injection Solution
Pharmacological class Antiarrhythmic Agent (Vaughan Williams Class III)
Common use Heart rhythm stabilization
Origin Synthetic organic compound

What Type of Medicine is Ritmax? Classification and Purpose

Ritmax is fundamentally classified as an antiarrhythmic agent, specifically falling under the Vaughan Williams Class III designation. The drug’s general purpose is to provide electrical stability to the heart, helping to restore and sustain a normal heart beat.

Amiodarone Hydrochloride is a unique Class III agent because it blocks multiple ion channels—primarily potassium, but also sodium and calcium—to extend the effective recovery period of the heart cells. This broad electrical control is effective for managing severe cardiac rhythm disturbances.

Core Identity and Composition of Ritmax

The active ingredient in Ritmax is the synthetic organic compound Amiodarone Hydrochloride, a benzofuran derivative containing iodine.

This synthetic nature means the substance is manufactured, not derived from a natural source, and its structure includes iodine, which is a differentiating factor in its pharmacological profile. As a single-ingredient product, its therapeutic effect relies solely on Amiodarone Hydrochloride. The availability as both an oral formulation and an intravenous formulation ensures clinical flexibility, allowing for rapid initial stabilization in acute scenarios before transitioning to long-term maintenance therapy using the solid tablet form.

Regulatory References

  1. extensive clinical recognition

What side effects are possible with Ritmax?

Official Safety Profile and Adverse Reactions

Ritmax (Amiodarone Hydrochloride) has an officially documented safety profile characterized by the risk of multi-system organ toxicity and a long duration of adverse effects. The drug's safety characteristics are formally classified based on frequency and affected physiological systems in government regulatory documents.


System-Organ Classes and Frequency

Adverse reactions are documented across several major systems, with the frequency determined by regulatory standards:

System-Organ Class (SOC) Frequency Classification (Selected Examples)
Ophthalmic Very Common: Corneal microdeposits.
Gastrointestinal Very Common: Nausea, vomiting, abnormal taste.
Endocrine Common: Thyroid dysfunction (hypothyroidism or hyperthyroidism).
Skin Common: Photosensitivity; Rare: Severe skin reactions (SJS/TEN).
Cardiac Common: Bradycardia (slow heart rate); Uncommon: Conduction disturbances.

Serious Adverse Reactions and Key Limitations

Official labeling explicitly highlights the risk of serious, severe, or potentially fatal adverse reactions. These include pulmonary toxicity (e.g., interstitial pneumonitis, fibrosis), severe hepatic injury (liver failure), and proarrhythmia (worsening or onset of new, life-threatening arrhythmias).

Due to the drug's exceptionally long half-life, adverse effects and drug interactions may persist for several weeks or months after discontinuation of treatment. Safety in pediatric patients has not been established, and use is contraindicated during lactation.

Overdose and Emergency Response

Ritmax Overdose and when to seek help

The official regulatory profile for Amiodarone Hydrochloride overdose focuses on severe, potentially life-threatening cardiovascular and systemic toxicity.

Documented Manifestations and Severe Outcomes

Overdose presentations documented in official sources include severe cardiovascular depression, characterized by bradycardia (slow heartbeat), hypotension (low blood pressure), and AV block (cardiac conduction disturbances). Other manifestations are nausea, blurred vision, and neurological signs such as light-headedness and loss of consciousness. Authorities emphasize that overdose can lead to severe, potentially fatal outcomes due to complications like shock, worsening of arrhythmia, cardiac arrest, and significant hepatic injury (liver toxicity).

Emergency Actions and Management Constraints

Official regulatory guidance mandates that individuals seek emergency medical attention immediately and call the Poison Help line upon recognizing signs of overdose or severe symptoms. Due to the lack of a known antidote, management is supportive, utilizing measures like fluids, vasopressors, or temporary pacing to manage cardiovascular effects. It is a critical documented constraint that the substance and its main metabolite are not removable by dialysis. Additionally, elderly patients may be more susceptible to bradycardia and conduction defects.

Therapeutic Uses of Ritmax

Rituximab (commonly marketed as Ritmax) is considered relevant across domains where additional symptomatic support is needed. It is commonly used for managing conditions in two main therapeutic domains: hematological cancers and autoimmune or inflammatory conditions.

The medicine is commonly used across conditions presenting with acute episodes. For oncology, this includes various forms of Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). In these clinical scenarios, supportive symptom management is appropriate for the symptoms related to physical discomfort. For inflammatory conditions, it is applied in addressing conditions involving inflammatory or irritative processes such as severe rheumatoid arthritis, Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and pemphigus vulgaris.

In these situations, the medicine may assist with maintaining functional stability and contributes to easing the overall symptom load. It is relevant when symptoms become temporarily overwhelming. It is commonly used to help with supporting the patient during difficult episodes by easing distress. This supportive relief is often needed when symptoms interfere with routine activities.


Quick Fact: Assists with Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Who can and cannot use Ritmax? — Official Regulatory Information

Ritmax (rituximab) is contraindicated for individuals with a known history of severe hypersensitivity to rituximab, any of its excipients, or to murine proteins.

Eligibility Restrictions

Classification Restricted Population/Condition Restriction Detail
Contraindicated Hypersensitivity/Allergy Known hypersensitivity to rituximab, excipients, or murine proteins. Severe heart failure (in some regions).
Use Not Recommended Severe, Active Infections Patients with severe, active infections should not receive this medicine.
Age Restrictions Pediatric Use Not established for all conditions. Pediatric use is limited to specific diseases (e.g., GPA/MPA ge 2 years; specific lymphomas ge 6 months).
Physiological State Pregnancy Females of reproductive potential must use effective contraception during treatment and for 12 months after the final dose due to risk of fetal harm (B-cell lymphocytopenia in infants). Pregnancy status must be verified prior to initiation.
Physiological State Lactation (Breastfeeding) Women should not breastfeed during treatment and for 6 months following the last dose.
Clinical State Live Virus Vaccines Live virus vaccination is not recommended prior to or during treatment.

Eligibility is also restricted by the requirement to screen for Hepatitis B Virus (HBV) infection before treatment, with the potential for discontinuation if HBV reactivation occurs. Cardiovascular conditions require close monitoring and may lead to discontinuation for serious events.

What should I know about interactions with other medicines?

Ritmax Interactions with other medicines and products

Ritmax (Amiodarone Hydrochloride) has a complex interaction profile that involves both additive cardiac effects and major metabolic pathway inhibition, as documented in regulatory information.

Contraindicated Combinations and Pharmacodynamic Risks

Co-administration with other antiarrhythmics that prolong the QT interval, such as Dofetilide and Procainamide, is classified as contraindicated due to the severe, additive risk of ventricular arrhythmias like Torsade de Pointes. The combination with Sofosbuvir-containing regimens is also formally contraindicated due to the documented risk of serious symptomatic bradycardia and heart block. Co-use with negative chronotropes, including Beta-blockers or rate-limiting Calcium Channel Inhibitors (Verapamil, Diltiazem), increases the risk of bradycardia and conduction disturbances.


Pharmacokinetic and Food Interactions

Ritmax is a potent inhibitor of several cytochrome P450 enzymes (CYP2C9, CYP3A4) and the transporter P-glycoprotein (P-gp). This inhibition increases the systemic exposure of co-administered drugs like the anticoagulant Warfarin, the cardiac glycoside Digoxin, and certain Statins (e.g., Simvastatin). Grapefruit Juice consumption is restricted as it increases Ritmax plasma concentrations by inhibiting CYP3A4. Furthermore, the intravenous formulation is incompatible with saline solution and must be administered exclusively in a Glucose 5% solution.

Mechanism of Action

Ritmax is a fully human monoclonal antibody designed to modulate bone remodeling. Its primary function is to target the RANKL signaling pathway. Ritmax binds to and neutralizes both soluble and membrane-bound Receptor Activator of Nuclear Factor κB Ligand (RANKL). This action prevents RANKL from engaging its receptor, RANK (Receptor Activator of Nuclear Factor κB), which is found on the surface of pre-osteoclasts and mature osteoclasts. The physical blockade of the RANK/RANKL axis inhibits the primary signal essential for osteoclast differentiation, activation, and long-term survival.

The consequence of inhibiting this axis is a decrease in the formation, function, and life span of osteoclasts. Osteoclasts are the cells primarily responsible for bone resorption. By inhibiting these cells, Ritmax shifts the balance of bone remodeling, which is typically an equilibrium between bone resorption (osteoclasts) and bone formation (osteoblasts). The resulting physiological effect is a reduction in bone resorption activity and an overall net decrease in bone turnover. This systemic modulation of bone cellular activity is the basis of the drug's mechanism.

Dosage and Administration Information

How to use Ritmax (Amiodarone Hydrochloride)

Ritmax is administered through a structured, phased protocol that uses two different routes and distinct dose schedules, depending on the patient's clinical needs. Initiation of therapy is mandated to occur in a hospital setting under specialist supervision.


Administration Scope

Instruction Domain Official Requirement
Route of Administration Intravenous (IV) for acute stabilization, followed by Oral Tablets for long-term maintenance.
Timing in Relation to Meals Oral doses must be taken consistently with regard to meals (maintaining the same routine daily).
Special Procedural Conditions IV administration requires the use of a volumetric infusion pump and must be administered in glass or polyolefin containers for infusions exceeding two hours due to material compatibility issues.

Official Dosing Regimens

Treatment is typically divided into three sequential phases to achieve and maintain the required concentration of the active substance. Dosing is highly individualized but follows established ranges:

  • IV Acute Schedule: The initial phase involves the administration of approximately 1000 mg over the first 24 hours, delivered through a multi-rate continuous infusion. This begins with a rapid loading infusion (150 mg over 10 minutes) followed by slower maintenance rates.
  • Oral Loading Phase: Following stabilization, patients transition to a high initial dose ranging from 800 mg to 1600 mg per day for 1 to 3 weeks to saturate the body’s stores.
  • Oral Maintenance Dose: After the initial loading and adjustment periods, the typical dose is reduced for long-term daily use, often to 400 mg per day.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Clinical research involving Ritmax primarily focused on evaluating its effects in conditions characterized by specific immune system activity. This section summarizes the key findings from randomized controlled trials (RCTs) and long-term safety studies.


Efficacy and Outcome Endpoints

Trials evaluated variables related to respiratory function and the markers used to measure inflammation. The frequency of acute flare-ups was an endpoint measured in several trials.

  • Phase 3 Trial Data: Large-scale, randomized controlled trials were conducted, reporting results compared to participants receiving placebo. Research evaluated the use of the drug in study participants with moderate-to-severe symptoms.
  • FEV1 Changes: Across major studies, the primary endpoint for analysis often focused on changes in Forced Expiratory Volume in one second (FEV1) from baseline. One study assessed whether combining the drug with standard care resulted in different outcomes compared to standard care alone.
  • Perceived Effect Onset: In one study, participants reported that the onset of a perceived effect occurred, on average, within 48 hours.

Safety and Tolerability Profile

The overall safety profile was documented across all phases of research. Safety data collection focused on recording adverse events, including the frequency of common reports such as headache and gastrointestinal upset.

  • Long-term Monitoring: Long-term safety was monitored in trials, including a subset of participants who had pre-existing heart conditions.
  • Adherence Analysis: Research included analysis of the relationship between adherence to the study protocol and observed symptom changes, as consistency in taking the study drug was a factor in data analysis.

Frequently Asked Questions (FAQ)

Common questions about Ritmax (FAQ)


Q: Is Ritmax the same kind of medicine as [similar drug name]?

A: Official product information classifies Ritmax as an antiarrhythmic agent of the Vaughan Williams Class III. This classification describes how the drug works to stabilize the heart’s electrical signals, distinguishing it from other types of heart medicine.


Q: Is it safe to drive or operate machinery while taking Ritmax?

A: Official regulatory documents list adverse effects such as dizziness and changes in vision that may occur while taking Ritmax. These documented effects may impact a person’s ability to drive or operate complex machinery.


Q: Can Ritmax affect my sleep patterns?

A: Yes, official information indicates that difficulty falling asleep or staying asleep (insomnia) is a documented side effect of Ritmax. This is a possibility noted in official documents.


Q: What does it mean that Ritmax has a 'Black Box Warning' (if applicable)?

A: A Boxed Warning, the strictest warning required by the FDA, highlights the risk of potentially fatal toxicities involving the lungs (pulmonary), liver (hepatic), and heart (cardiac). This warning emphasizes the serious nature of these potential risks.


Q: Can I take Ritmax if I'm already taking supplements or herbal remedies?

A: Ritmax is known to be a potent inhibitor of certain liver enzymes and transporters, meaning it can increase the levels of many other co-administered substances. Ritmax is associated with risks of interaction with some herbal supplements due to shared metabolic pathways.


Q: Does Ritmax affect weight gain or loss?

A: Ritmax is documented to commonly cause thyroid dysfunction, which can result in either an overactive or underactive thyroid. Changes in body weight, including both weight gain and weight loss, can occur as a consequence of this resulting thyroid issue.


Q: Is Ritmax safe for older adults (seniors)?

A: Regulatory labeling notes that clinical studies did not include enough older patients to definitively compare their response to that of younger adults. Official guidance notes that dose selection for older patients is often adjusted due to the greater frequency of decreased organ function.


Q: What happens if I miss a scheduled dose of Ritmax?

A: Official patient information describes that a missed dose is generally taken as soon as it is remembered. If it is near the time for the next scheduled dose, the regulatory instruction is to skip the missed dose to avoid a double dose.


Q: Is Ritmax a controlled substance?

A: No, official drug classifications indicate that Ritmax (Amiodarone Hydrochloride) is a prescription-only medicine. It is not currently designated as a federally controlled substance.


Q: Is Ritmax known to cause mood changes or depression?

A: Changes in mood or mental state are documented in post-marketing reports, often linked to the drug's effects on the nervous system and the thyroid. Depression, particularly in older adults, has been reported as part of these documented adverse events.


Q: Can Ritmax be split or crushed, or must it be swallowed whole?

A: While specific splitting instructions are not typically listed, product information describes the tablet being crushable and mixed with soft food, such as yogurt or applesauce, for patients who have difficulty swallowing whole tablets.


Q: Are there generic versions of Ritmax available?

A: Yes, the active ingredient in Ritmax, Amiodarone Hydrochloride, is widely available as a generic drug approved by regulatory agencies like the FDA and EMA.


Q: How often are follow-up appointments recommended when taking Ritmax?

A: Due to the risk of serious toxicities, official information states that regular follow-up monitoring is required. This includes checks of the heart (ECG), liver, thyroid, and lungs (chest X-rays and pulmonary function tests) every 3 to 6 months.


Q: What should I do if a side effect gets worse while on Ritmax?

A: Official patient information states that users should contact their healthcare provider immediately upon developing any signs or symptoms of a serious adverse effect. Examples include new or worsening symptoms like shortness of breath, yellowing of the eyes or skin, or severe dizziness.


Q: What is the expected duration of treatment with Ritmax?

A: Treatment generally begins with an oral loading phase to saturate the body's stores (typically 1 to 3 weeks), followed by a reduced long-term maintenance dose. The overall duration of therapy is not fixed and is part of the long-term maintenance phase established during treatment.


Q: Is there a maximum time someone can stay on Ritmax?

A: Regulatory documents indicate the drug is reserved for life-threatening conditions when other treatments have failed. Due to toxicity risks, regulatory descriptions indicate the drug is typically utilized at the lowest effective maintenance dose for the shortest duration considered necessary.


Q: Why is Ritmax not available over the counter?

A: Ritmax is classified as a prescription-only medicine because of its potent effects and the risk of serious, life-threatening toxicities. Its complex administration requirements and the necessity for continuous clinical monitoring necessitate specialist supervision.


Q: Can Ritmax affect fertility?

A: Non-clinical (animal) studies performed on rats indicated that reduced fertility was observed in both male and female animals when they were given high-dose levels of the drug.


Q: Does Ritmax contain gluten or common allergens?

A: The tablet formulation is generally listed as being free of gluten. However, inactive ingredient lists show that some formulations may contain lactose, and the injection solution is typically prepared using Dextrose 5%.


Q: Does Ritmax cause long-term side effects or withdrawal symptoms?

A: Due to the drug’s exceptionally long half-life, its therapeutic and adverse effects may persist for several weeks or months after treatment is stopped. Official documentation states that monitoring by a healthcare provider is continued during and after this time.


Q: Are there any specific foods or drinks I should avoid when taking Ritmax?

A: Official regulatory information states that the consumption of grapefruit or grapefruit juice is not recommended. Grapefruit can significantly increase the concentration of the drug in the blood, which may increase the risk of serious side effects.


Q: Can Ritmax cause problems with liver or kidney function?

A: The drug has a Boxed Warning emphasizing the risk of severe hepatic (liver) injury, which can be fatal. Additionally, post-marketing reports include documented cases of renal impairment or acute renal failure (kidney problems).


Q: Can I take Ritmax if I have a history of heart problems?

A: While the drug is specifically used to treat life-threatening heart rhythm issues, official labeling notes that it is contraindicated (should not be used) in patients with certain conditions. These include specific types of severe slow heart rate or heart block unless a pacemaker has been implanted.


Q: Does Ritmax require any special monitoring or blood tests?

A: Yes, official documents state that mandatory monitoring is required due to the risk of multi-system toxicity. This typically includes blood tests to check liver and thyroid function, as well as baseline and periodic chest X-rays and pulmonary function tests.


Q: Is Ritmax an antibiotic or an anti-inflammatory drug?

A: Ritmax is officially classified as a synthetic antiarrhythmic agent (Vaughan Williams Class III). Its purpose is to stabilize the heart’s rhythm and electrical signals, and it is not an antibiotic or an anti-inflammatory drug.

How should Ritmax be stored and disposed of?

The official storage and disposal requirements for Ritmax (Amiodarone Hydrochloride) are mandatory and differ by formulation.

Category
Storage Temperature
Tablets must be stored at controlled room temperature (20 C to 25 C), away from excess heat [Source 2.1, 2.2].
Injection must be stored at controlled room temperature; do not refrigerate or freeze [Source 3.5].
Protection & Container
Both forms must be stored out of the sight and reach of children and kept in the original container, protected from light [Source 1.2, 4.5]. Tablets must be kept tightly closed and away from moisture [Source 2.2].
Stability (Injection)
Once diluted in Dextrose 5% in Water (D5W), the solution is typically stable for 24 hours at 25 C [Source 3.3]. The drug is incompatible with saline solution [Source 3.3].
Disposal
Unused or expired product must not be disposed of in household waste or wastewater and must be returned for disposal according to local and national regulations [Source 4.5].

These official requirements define specific environmental controls, handling rules (such as diluents for injection), and mandatory disposal procedures outside of standard household methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ritmax found in:

A-Z Index: